In gliomas, HOXA3, A7, A9, and A10 are methylation targets mainly in high-grade tumors, and their role as potential biomarkers has been proposed to clinically distinguish among patient subgroups [84]. The gene discussed is HOXA3; the disease is central nervous system cancer.